In HCC, the ability to recognize TAAs by CD8+ T cells is determined by the specificity of the epitope and appears to be dependent on the stage of cancer, since the highest ability of CD8+ T cells to respond to a specific TAA is observed in the early stages of cancer and is a favorable prognostic factor. This evidence concerns the gene CD8A and cancer.